NVO logo

NVO
Novo Nordisk A/S

30,719
Mkt Cap
$129.98B
Volume
15.63M
52W High
$82.57
52W Low
$35.85
PE Ratio
11.11
NVO Fundamentals
Price
$38.58
Prev Close
$39.07
Open
$38.58
50D MA
$51.29
Beta
0.89
Avg. Volume
31.81M
EPS (Annual)
$3.49
P/B
5.62
Rev/Employee
$679,358.45
$242,651.58
Loading...
Loading...
News
all
press releases
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP 1 Market?
Key PointsNovo Nordisk shares look cheap, but execution and management changes weigh on investor confidence...
Nasdaq News: Markets·2h ago
News Placeholder
More News
News Placeholder
Novo Nordisk A/S (NYSE:NVO) Trading Down 1.2% - What's Next?
Novo Nordisk A/S (NYSE:NVO) Trading Down 1.2% - Here's Why...
MarketBeat·3h ago
News Placeholder
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.
Zacks·9h ago
News Placeholder
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks·11h ago
News Placeholder
Walled Lake Planning & Wealth Management LLC Sells 26,807 Shares of Novo Nordisk A/S $NVO
Walled Lake Planning & Wealth Management LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 70.7% in the third quarter, according to the company in its most recent 13F filing...
MarketBeat·12h ago
News Placeholder
The US Leads The World In The Weight-Loss Injection Boom
The US Leads The World In The Weight-Loss Injection Boom Novo Nordisk's obesity-drug franchise has surged at a remarkable pace. In just four years, revenue from its weight-management treatments...
Zero Hedge·15h ago
News Placeholder
Novo Nordisk A/S $NVO is Foresight Global Investors Inc.'s 10th Largest Position
Foresight Global Investors Inc. cut its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·16h ago
News Placeholder
Novo Nordisk A/S (NYSE:NVO) Stock Price Up 1.4% - What's Next?
Novo Nordisk A/S (NYSE:NVO) Trading 1.4% Higher - Here's Why...
MarketBeat·1d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk...
PR Newswire·1d ago
News Placeholder
Promising Pharmaceutical Stocks To Watch Now - March 5th
Eli Lilly and Company, AbbVie, McKesson, Pfizer, and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are...
MarketBeat·1d ago
<
1
2
...
>

Latest NVO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.